Weight Loss Steady Unexplained
Merck Medical Research boceprevir achieved significantly higher SVR rate in non-treatment and treatment … BOSTON – (BUSINESS WIRE) – Company Merck announced the final results today from two pivotal Phase III boceprevir, its oral protease inhibitor against experimental hepatitis C showed a significantly higher virological response (SVR) rates in an adult patient failed treatment (treatment failure, patients respond to HCV-2) and in adults who were new to treatment (treatment-naive …
You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.











